The University of Michigan has been participating as a funded member of the Southwest Oncology Group (SWOG) since January 1, 1980. SWOG participation is an Important component of a large cancer research effort at U of M. We remain committed to the concept that multi-institutional collaboration is essential to the advancement of cancer research. On behalf of the University, Dr. Kenneth Pienta has received the first Team Science Award given by the American Association of Cancer Research (AACR) for the collaborative efforts of teams from the University of Michigan and Brigham and Women's Hospital (Boston, MA). Our goal, as a member institution of SWOG, is to make significant scientific, administrative and patient data contributions to the Group's effort to study and improve cancer therapy. The cooperative group process involves the collection of patient data, adoption of uniform toxicity and response criteria, and conduction of purposeful clinical trials as well as introducing the concept of merging """"""""SPORES"""""""" ino the cooperative group mechanism. Cooperative groups have provided the only setting in which the sophisticated concepts of combined modality and adjuvant therapies can be properly Investigated. The cooperative groups have also produced an improved understanding of the Important relatioinships between prognostic factors, therapy and patient survival that could not have been obtained otherwise.

Public Health Relevance

Participation in SWOG is multidisciplinary with membership that clinical and basic research associates involved in group activities. It is characterized by data management and protocol compliance, administrative and scientific contributions, and patient registration contributions. Patient accrual is expected to increase to 15-20 patients per year with increased commitment among SWOG investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA027057-33
Application #
8213587
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1980-01-01
Project End
2015-12-31
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
33
Fiscal Year
2012
Total Cost
$400,987
Indirect Cost
$83,144
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Schott, Anne F; Barlow, William E; Van Poznak, Catherine H et al. (2016) Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Res Treat 159:87-95
Prebet, Thomas; Sun, Zhuoxin; Ketterling, Rhett P et al. (2016) Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. Br J Haematol 172:384-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Whelan, Timothy J; Olivotto, Ivo A; Parulekar, Wendy R et al. (2015) Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med 373:307-16
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-40
Coutre, Steven E; Othus, Megan; Powell, Bayard et al. (2014) Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol 165:497-503
Zeidan, Amer M; Lee, Ju-Whei; Prebet, Thomas et al. (2014) Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS. Br J Haematol 167:62-8
Malhotra, Binu; Moon, James; Kucuk, Omar et al. (2014) Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329. Head Neck 36:1712-7

Showing the most recent 10 out of 189 publications